PMC:7104244 / 3850-5145 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"58","span":{"begin":11,"end":21},"obj":"Species"},{"id":"59","span":{"begin":618,"end":628},"obj":"Species"},{"id":"60","span":{"begin":1118,"end":1128},"obj":"Species"},{"id":"61","span":{"begin":1274,"end":1284},"obj":"Species"},{"id":"62","span":{"begin":207,"end":215},"obj":"Disease"},{"id":"63","span":{"begin":236,"end":241},"obj":"Disease"},{"id":"64","span":{"begin":243,"end":250},"obj":"Disease"},{"id":"65","span":{"begin":252,"end":261},"obj":"Disease"},{"id":"66","span":{"begin":263,"end":270},"obj":"Disease"},{"id":"67","span":{"begin":272,"end":280},"obj":"Disease"},{"id":"68","span":{"begin":286,"end":294},"obj":"Disease"},{"id":"69","span":{"begin":394,"end":402},"obj":"Disease"},{"id":"70","span":{"begin":462,"end":471},"obj":"Disease"},{"id":"71","span":{"begin":1261,"end":1269},"obj":"Disease"}],"attributes":[{"id":"A58","pred":"tao:has_database_id","subj":"58","obj":"Tax:2697049"},{"id":"A59","pred":"tao:has_database_id","subj":"59","obj":"Tax:2697049"},{"id":"A60","pred":"tao:has_database_id","subj":"60","obj":"Tax:2697049"},{"id":"A61","pred":"tao:has_database_id","subj":"61","obj":"Tax:2697049"},{"id":"A62","pred":"tao:has_database_id","subj":"62","obj":"MESH:C000657245"},{"id":"A63","pred":"tao:has_database_id","subj":"63","obj":"MESH:D005334"},{"id":"A64","pred":"tao:has_database_id","subj":"64","obj":"MESH:D005221"},{"id":"A65","pred":"tao:has_database_id","subj":"65","obj":"MESH:D003371"},{"id":"A66","pred":"tao:has_database_id","subj":"66","obj":"MESH:D063806"},{"id":"A67","pred":"tao:has_database_id","subj":"67","obj":"MESH:D004417"},{"id":"A68","pred":"tao:has_database_id","subj":"68","obj":"MESH:D006261"},{"id":"A69","pred":"tao:has_database_id","subj":"69","obj":"MESH:C000657245"},{"id":"A70","pred":"tao:has_database_id","subj":"70","obj":"MESH:D007239"},{"id":"A71","pred":"tao:has_database_id","subj":"71","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"To prevent SARS-CoV-2 transmission, we propose additions to the current donor screening measures. In all countries, before each donation, physicians should screen for two main items: the presence of typical COVID-19 symptoms (including fever, fatigue, dry cough, myalgia, dyspnoea, and headache) within the previous 30 days; and the donor's history of travel to regions known to be affected by COVID-19 or close contact with individuals with proven or suspected infection, within the previous 30 days. If either of these items is positive, the potential donor should either be rejected or tested with RT-PCR assay for SARS-CoV-2. In endemic countries, the RT-PCR assay should be considered in all donors, even if they are asymptomatic or do not have a history of high-risk travel or contact. Alternatively, donor stools should be stored and quarantined for 30 days before use, and released only if the donor has not developed symptoms. Finally, stool banks should retrospectively check the health status of the donor before using frozen faeces, according to local epidemiology, to avoid further potential spreading of SARS-CoV-2. These suggestions should be tailored to local health-care organisations, and should be updated accordingly as further insight into COVID-19 and SARS-CoV-2 is gained."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T49","span":{"begin":11,"end":21},"obj":"SP_7"},{"id":"T48","span":{"begin":207,"end":215},"obj":"SP_7"},{"id":"T47","span":{"begin":256,"end":261},"obj":"UBERON:0002048"},{"id":"T46","span":{"begin":394,"end":402},"obj":"SP_7"},{"id":"T45","span":{"begin":425,"end":436},"obj":"NCBITaxon:1"},{"id":"T44","span":{"begin":618,"end":628},"obj":"SP_7"},{"id":"T43","span":{"begin":813,"end":819},"obj":"UBERON:0001988"},{"id":"T42","span":{"begin":945,"end":950},"obj":"UBERON:0001988"},{"id":"T41","span":{"begin":1037,"end":1043},"obj":"UBERON:0001988"},{"id":"T40","span":{"begin":1118,"end":1128},"obj":"SP_7"},{"id":"T39","span":{"begin":1261,"end":1269},"obj":"SP_7"},{"id":"T38","span":{"begin":1274,"end":1284},"obj":"SP_7"}],"text":"To prevent SARS-CoV-2 transmission, we propose additions to the current donor screening measures. In all countries, before each donation, physicians should screen for two main items: the presence of typical COVID-19 symptoms (including fever, fatigue, dry cough, myalgia, dyspnoea, and headache) within the previous 30 days; and the donor's history of travel to regions known to be affected by COVID-19 or close contact with individuals with proven or suspected infection, within the previous 30 days. If either of these items is positive, the potential donor should either be rejected or tested with RT-PCR assay for SARS-CoV-2. In endemic countries, the RT-PCR assay should be considered in all donors, even if they are asymptomatic or do not have a history of high-risk travel or contact. Alternatively, donor stools should be stored and quarantined for 30 days before use, and released only if the donor has not developed symptoms. Finally, stool banks should retrospectively check the health status of the donor before using frozen faeces, according to local epidemiology, to avoid further potential spreading of SARS-CoV-2. These suggestions should be tailored to local health-care organisations, and should be updated accordingly as further insight into COVID-19 and SARS-CoV-2 is gained."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T24","span":{"begin":813,"end":819},"obj":"Body_part"},{"id":"T25","span":{"begin":945,"end":950},"obj":"Body_part"},{"id":"T26","span":{"begin":1037,"end":1043},"obj":"Body_part"}],"attributes":[{"id":"A24","pred":"fma_id","subj":"T24","obj":"http://purl.org/sig/ont/fma/fma64183"},{"id":"A25","pred":"fma_id","subj":"T25","obj":"http://purl.org/sig/ont/fma/fma64183"},{"id":"A26","pred":"fma_id","subj":"T26","obj":"http://purl.org/sig/ont/fma/fma64183"}],"text":"To prevent SARS-CoV-2 transmission, we propose additions to the current donor screening measures. In all countries, before each donation, physicians should screen for two main items: the presence of typical COVID-19 symptoms (including fever, fatigue, dry cough, myalgia, dyspnoea, and headache) within the previous 30 days; and the donor's history of travel to regions known to be affected by COVID-19 or close contact with individuals with proven or suspected infection, within the previous 30 days. If either of these items is positive, the potential donor should either be rejected or tested with RT-PCR assay for SARS-CoV-2. In endemic countries, the RT-PCR assay should be considered in all donors, even if they are asymptomatic or do not have a history of high-risk travel or contact. Alternatively, donor stools should be stored and quarantined for 30 days before use, and released only if the donor has not developed symptoms. Finally, stool banks should retrospectively check the health status of the donor before using frozen faeces, according to local epidemiology, to avoid further potential spreading of SARS-CoV-2. These suggestions should be tailored to local health-care organisations, and should be updated accordingly as further insight into COVID-19 and SARS-CoV-2 is gained."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T16","span":{"begin":813,"end":819},"obj":"Body_part"},{"id":"T17","span":{"begin":945,"end":950},"obj":"Body_part"},{"id":"T18","span":{"begin":1037,"end":1043},"obj":"Body_part"}],"attributes":[{"id":"A16","pred":"uberon_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/UBERON_0001988"},{"id":"A17","pred":"uberon_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/UBERON_0001988"},{"id":"A18","pred":"uberon_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/UBERON_0001988"}],"text":"To prevent SARS-CoV-2 transmission, we propose additions to the current donor screening measures. In all countries, before each donation, physicians should screen for two main items: the presence of typical COVID-19 symptoms (including fever, fatigue, dry cough, myalgia, dyspnoea, and headache) within the previous 30 days; and the donor's history of travel to regions known to be affected by COVID-19 or close contact with individuals with proven or suspected infection, within the previous 30 days. If either of these items is positive, the potential donor should either be rejected or tested with RT-PCR assay for SARS-CoV-2. In endemic countries, the RT-PCR assay should be considered in all donors, even if they are asymptomatic or do not have a history of high-risk travel or contact. Alternatively, donor stools should be stored and quarantined for 30 days before use, and released only if the donor has not developed symptoms. Finally, stool banks should retrospectively check the health status of the donor before using frozen faeces, according to local epidemiology, to avoid further potential spreading of SARS-CoV-2. These suggestions should be tailored to local health-care organisations, and should be updated accordingly as further insight into COVID-19 and SARS-CoV-2 is gained."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T16","span":{"begin":11,"end":19},"obj":"Disease"},{"id":"T17","span":{"begin":207,"end":215},"obj":"Disease"},{"id":"T18","span":{"begin":394,"end":402},"obj":"Disease"},{"id":"T19","span":{"begin":462,"end":471},"obj":"Disease"},{"id":"T20","span":{"begin":618,"end":626},"obj":"Disease"},{"id":"T21","span":{"begin":1118,"end":1126},"obj":"Disease"},{"id":"T22","span":{"begin":1261,"end":1269},"obj":"Disease"},{"id":"T23","span":{"begin":1274,"end":1282},"obj":"Disease"}],"attributes":[{"id":"A16","pred":"mondo_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A17","pred":"mondo_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A18","pred":"mondo_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A19","pred":"mondo_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A20","pred":"mondo_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A21","pred":"mondo_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A22","pred":"mondo_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A23","pred":"mondo_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"To prevent SARS-CoV-2 transmission, we propose additions to the current donor screening measures. In all countries, before each donation, physicians should screen for two main items: the presence of typical COVID-19 symptoms (including fever, fatigue, dry cough, myalgia, dyspnoea, and headache) within the previous 30 days; and the donor's history of travel to regions known to be affected by COVID-19 or close contact with individuals with proven or suspected infection, within the previous 30 days. If either of these items is positive, the potential donor should either be rejected or tested with RT-PCR assay for SARS-CoV-2. In endemic countries, the RT-PCR assay should be considered in all donors, even if they are asymptomatic or do not have a history of high-risk travel or contact. Alternatively, donor stools should be stored and quarantined for 30 days before use, and released only if the donor has not developed symptoms. Finally, stool banks should retrospectively check the health status of the donor before using frozen faeces, according to local epidemiology, to avoid further potential spreading of SARS-CoV-2. These suggestions should be tailored to local health-care organisations, and should be updated accordingly as further insight into COVID-19 and SARS-CoV-2 is gained."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T34","span":{"begin":589,"end":595},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T35","span":{"begin":750,"end":751},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T36","span":{"begin":908,"end":911},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T37","span":{"begin":1188,"end":1201},"obj":"http://purl.obolibrary.org/obo/OBI_0000245"}],"text":"To prevent SARS-CoV-2 transmission, we propose additions to the current donor screening measures. In all countries, before each donation, physicians should screen for two main items: the presence of typical COVID-19 symptoms (including fever, fatigue, dry cough, myalgia, dyspnoea, and headache) within the previous 30 days; and the donor's history of travel to regions known to be affected by COVID-19 or close contact with individuals with proven or suspected infection, within the previous 30 days. If either of these items is positive, the potential donor should either be rejected or tested with RT-PCR assay for SARS-CoV-2. In endemic countries, the RT-PCR assay should be considered in all donors, even if they are asymptomatic or do not have a history of high-risk travel or contact. Alternatively, donor stools should be stored and quarantined for 30 days before use, and released only if the donor has not developed symptoms. Finally, stool banks should retrospectively check the health status of the donor before using frozen faeces, according to local epidemiology, to avoid further potential spreading of SARS-CoV-2. These suggestions should be tailored to local health-care organisations, and should be updated accordingly as further insight into COVID-19 and SARS-CoV-2 is gained."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T6","span":{"begin":72,"end":77},"obj":"Chemical"},{"id":"T7","span":{"begin":554,"end":559},"obj":"Chemical"},{"id":"T8","span":{"begin":807,"end":812},"obj":"Chemical"},{"id":"T9","span":{"begin":902,"end":907},"obj":"Chemical"},{"id":"T10","span":{"begin":1011,"end":1016},"obj":"Chemical"}],"attributes":[{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_17891"},{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_17891"},{"id":"A8","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_17891"},{"id":"A9","pred":"chebi_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_17891"},{"id":"A10","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_17891"}],"text":"To prevent SARS-CoV-2 transmission, we propose additions to the current donor screening measures. In all countries, before each donation, physicians should screen for two main items: the presence of typical COVID-19 symptoms (including fever, fatigue, dry cough, myalgia, dyspnoea, and headache) within the previous 30 days; and the donor's history of travel to regions known to be affected by COVID-19 or close contact with individuals with proven or suspected infection, within the previous 30 days. If either of these items is positive, the potential donor should either be rejected or tested with RT-PCR assay for SARS-CoV-2. In endemic countries, the RT-PCR assay should be considered in all donors, even if they are asymptomatic or do not have a history of high-risk travel or contact. Alternatively, donor stools should be stored and quarantined for 30 days before use, and released only if the donor has not developed symptoms. Finally, stool banks should retrospectively check the health status of the donor before using frozen faeces, according to local epidemiology, to avoid further potential spreading of SARS-CoV-2. These suggestions should be tailored to local health-care organisations, and should be updated accordingly as further insight into COVID-19 and SARS-CoV-2 is gained."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T1","span":{"begin":236,"end":241},"obj":"Phenotype"},{"id":"T2","span":{"begin":243,"end":250},"obj":"Phenotype"},{"id":"T3","span":{"begin":252,"end":261},"obj":"Phenotype"},{"id":"T4","span":{"begin":263,"end":270},"obj":"Phenotype"},{"id":"T5","span":{"begin":272,"end":280},"obj":"Phenotype"},{"id":"T6","span":{"begin":286,"end":294},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0012378"},{"id":"A3","pred":"hp_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/HP_0031246"},{"id":"A4","pred":"hp_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/HP_0003326"},{"id":"A5","pred":"hp_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/HP_0002094"},{"id":"A6","pred":"hp_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/HP_0002315"}],"text":"To prevent SARS-CoV-2 transmission, we propose additions to the current donor screening measures. In all countries, before each donation, physicians should screen for two main items: the presence of typical COVID-19 symptoms (including fever, fatigue, dry cough, myalgia, dyspnoea, and headache) within the previous 30 days; and the donor's history of travel to regions known to be affected by COVID-19 or close contact with individuals with proven or suspected infection, within the previous 30 days. If either of these items is positive, the potential donor should either be rejected or tested with RT-PCR assay for SARS-CoV-2. In endemic countries, the RT-PCR assay should be considered in all donors, even if they are asymptomatic or do not have a history of high-risk travel or contact. Alternatively, donor stools should be stored and quarantined for 30 days before use, and released only if the donor has not developed symptoms. Finally, stool banks should retrospectively check the health status of the donor before using frozen faeces, according to local epidemiology, to avoid further potential spreading of SARS-CoV-2. These suggestions should be tailored to local health-care organisations, and should be updated accordingly as further insight into COVID-19 and SARS-CoV-2 is gained."}

{"project":"LitCovid-sentences","denotations":[{"id":"T11","span":{"begin":0,"end":97},"obj":"Sentence"},{"id":"T12","span":{"begin":98,"end":501},"obj":"Sentence"},{"id":"T13","span":{"begin":502,"end":629},"obj":"Sentence"},{"id":"T14","span":{"begin":630,"end":791},"obj":"Sentence"},{"id":"T15","span":{"begin":792,"end":935},"obj":"Sentence"},{"id":"T16","span":{"begin":936,"end":1129},"obj":"Sentence"},{"id":"T17","span":{"begin":1130,"end":1295},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"To prevent SARS-CoV-2 transmission, we propose additions to the current donor screening measures. In all countries, before each donation, physicians should screen for two main items: the presence of typical COVID-19 symptoms (including fever, fatigue, dry cough, myalgia, dyspnoea, and headache) within the previous 30 days; and the donor's history of travel to regions known to be affected by COVID-19 or close contact with individuals with proven or suspected infection, within the previous 30 days. If either of these items is positive, the potential donor should either be rejected or tested with RT-PCR assay for SARS-CoV-2. In endemic countries, the RT-PCR assay should be considered in all donors, even if they are asymptomatic or do not have a history of high-risk travel or contact. Alternatively, donor stools should be stored and quarantined for 30 days before use, and released only if the donor has not developed symptoms. Finally, stool banks should retrospectively check the health status of the donor before using frozen faeces, according to local epidemiology, to avoid further potential spreading of SARS-CoV-2. These suggestions should be tailored to local health-care organisations, and should be updated accordingly as further insight into COVID-19 and SARS-CoV-2 is gained."}